NASDAQ:BIAF bioAffinity Technologies Q3 2026 Earnings Results & Report $2.38 +0.12 (+5.35%) As of 03:10 PM Eastern This is a fair market value price provided by Massive. Learn more. bioAffinity Technologies beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 6, 2026. The company reported EPS of -$3.94 versus the -$31.50 consensus estimate, while revenue of $1.07 million fell short of the $1.91 million estimate by $834.72 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 6, 2026TimeAfter Market ClosesConference Call7:00 AM ET bioAffinity Technologies EPS ResultsActual EPS-$3.94Consensus EPS -$31.50Beat/MissBeat by +$27.56One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersbioAffinity Technologies Revenue ResultsActual Revenue$1.07 millionExpected Revenue$1.91 millionBeat/MissMissed by -$834.72 thousandYoY Revenue GrowthN/AUpcoming EarningsbioAffinity Technologies' Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) bioAffinity Technologies Q3 2026 Earnings FAQ Did bioAffinity Technologies beat earnings estimates for Q3 2026? bioAffinity Technologies (NASDAQ:BIAF) reported earnings of -$3.94 per share for Q3 2026, beating the consensus estimate of -$31.50. The report was announced on Friday, November 6, 2026. What was bioAffinity Technologies' revenue for Q3 2026? bioAffinity Technologies reported revenue of $1.07 million for Q3 2026, against a consensus estimate of $1.91 million. When is bioAffinity Technologies' next earnings date? bioAffinity Technologies' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for bioAffinity Technologies on the company's earnings history page. bioAffinity Technologies Earnings HeadlinesbioAffinity Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath® Lung CommercializationNovember 6, 2026 | businesswire.combioAffinity Technologies Highlights Importance of Link Between Early Lung Cancer Detection and Curative Treatment During National Lung Cancer Awareness MonthOctober 29, 2026 | finance.yahoo.comThe Withdrawal You'll Never See on Your StatementA proposal circulating in Washington, dubbed the Mar-a-Lago Accord, calls for tariffs and currency pressure to deliberately weaken the US dollar, making American exports cheaper. For savers, a weaker dollar can quietly reduce purchasing power even if account balances stay the same. Bishop Gold Group's free 2026 Gold IRA Guide explains how physical gold can be held inside a retirement account, including a common rollover mistake that can trigger a taxable distribution.November 10 at 1:00 AM | Bishop Gold Group (Ad)bioAffinity highlights CyPath Lung at CHEST 2026October 15, 2026 | tipranks.combioAffinity to Present New Sputum-Based Lung Biomarker DataOctober 13, 2026 | tipranks.comBioAffinity Technologies Closes $4 Million Direct Offering, Private PlacementOctober 9, 2026 | finance.yahoo.comSee More bioAffinity Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email. Email Address About bioAffinity TechnologiesbioAffinity Technologies (NASDAQ:BIAF) is a biotechnology company focused on developing diagnostic and therapeutic products for cancer and other serious diseases. The company’s platform uses porphyrin-based compounds designed to selectively identify or target abnormal cells, with the goal of supporting earlier disease detection and more precise treatment. Its lead diagnostic product, CyPath Lung, is an investigational, noninvasive urine test intended to aid in the detection of lung cancer. The test uses an inhaled porphyrin compound that can bind to cancer cells in the lungs; the resulting material is collected in urine and analyzed using laboratory methods. CyPath Lung is designed to complement existing lung-cancer screening and diagnostic procedures, rather than replace them. bioAffinity is also developing therapeutic applications of its technology for cancer and other diseases. The company is based in Albuquerque, New Mexico, and conducts its research, product development and clinical activities in the United States. Its products remain subject to applicable regulatory review and authorization before they can be broadly marketed.View bioAffinity Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
